HUBEI BIOCAUSE PHARMACEUTICAL CO., LTD. Financials Hubei Biocause Pharmaceutical Co., Ltd.
Equities
000627
CNE000000F48
Life & Health Insurance
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.31 CNY | +0.87% |
|
-2.94% | -18.66% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 27,717 | 34,782 | 24,061 | 16,353 | 15,612 | 14,031 |
| Enterprise Value (EV) 1 | 14,167 | 27,982 | 4,655 | 8,772 | 17,373 | 11,297 |
| P/E ratio | 20.8 x | 19.6 x | 40.6 x | 33.1 x | 52.7 x | -21.8 x |
| Yield | 0.53% | 1.85% | 0.21% | 0.15% | 3.48% | - |
| Capitalization / Revenue | 0.93 x | 0.7 x | 0.59 x | 0.34 x | 0.32 x | 0.28 x |
| EV / Revenue | 0.47 x | 0.56 x | 0.11 x | 0.18 x | 0.35 x | 0.23 x |
| EV / EBITDA | 5.18 x | 7.94 x | 4 x | 22.6 x | 88.3 x | -28.5 x |
| EV / FCF | 2.54 x | 36.8 x | -0.45 x | -4.6 x | -7.69 x | 1.19 x |
| FCF Yield | 39.3% | 2.72% | -220% | -21.7% | -13% | 84.3% |
| Price to Book | 1.46 x | 1.64 x | 1.14 x | 0.73 x | 0.73 x | 0.68 x |
| Nbr of stocks (in thousands) | 49,40,629 | 49,40,629 | 49,40,629 | 49,40,629 | 49,40,629 | 49,40,629 |
| Reference price 2 | 5.610 | 7.040 | 4.870 | 3.310 | 3.160 | 2.840 |
| Announcement Date | 28/04/19 | 14/04/20 | 29/04/21 | 29/04/22 | 21/04/23 | 29/04/24 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 29,879 | 49,673 | 41,128 | 48,697 | 49,312 | 49,660 |
| EBITDA 1 | 2,733 | 3,523 | 1,163 | 388.8 | 196.8 | -396.3 |
| EBIT 1 | 2,640 | 3,444 | 1,100 | 300.6 | 105.9 | -497.5 |
| Operating Margin | 8.84% | 6.93% | 2.67% | 0.62% | 0.21% | -1% |
| Earnings before Tax (EBT) 1 | 2,636 | 3,633 | 1,449 | 343.1 | 224.8 | -1,868 |
| Net income 1 | 1,327 | 1,776 | 580.3 | 470.7 | 274.1 | -651.8 |
| Net margin | 4.44% | 3.58% | 1.41% | 0.97% | 0.56% | -1.31% |
| EPS 2 | 0.2700 | 0.3600 | 0.1200 | 0.1000 | 0.0600 | -0.1300 |
| Free Cash Flow 1 | 5,572 | 761.2 | -10,255 | -1,907 | -2,260 | 9,528 |
| FCF margin | 18.65% | 1.53% | -24.94% | -3.92% | -4.58% | 19.19% |
| FCF Conversion (EBITDA) | 203.91% | 21.61% | - | - | - | - |
| FCF Conversion (Net income) | 420.05% | 42.86% | - | - | - | - |
| Dividend per Share 2 | 0.0300 | 0.1300 | 0.0100 | 0.005000 | 0.1100 | - |
| Announcement Date | 28/04/19 | 14/04/20 | 29/04/21 | 29/04/22 | 21/04/23 | 29/04/24 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | 1,760 | - |
| Net Cash position 1 | 13,550 | 6,800 | 19,405 | 7,582 | - | 2,735 |
| Leverage (Debt/EBITDA) | - | - | - | - | 8.945 x | - |
| Free Cash Flow 1 | 5,572 | 761 | -10,255 | -1,907 | -2,260 | 9,528 |
| ROE (net income / shareholders' equity) | 9.02% | 9.67% | 3.24% | 2.44% | 1.42% | -3.76% |
| ROA (Net income/ Total Assets) | 1.04% | 1.12% | 0.31% | 0.07% | 0.02% | -0.11% |
| Assets 1 | 1,28,104 | 1,58,227 | 1,87,736 | 6,30,983 | 11,46,657 | 6,18,954 |
| Book Value Per Share 2 | 3.840 | 4.300 | 4.280 | 4.560 | 4.330 | 4.170 |
| Cash Flow per Share 2 | 3.700 | 2.630 | 5.440 | 4.710 | 5.330 | 5.700 |
| Capex 1 | 275 | 717 | 320 | 287 | 135 | 67.5 |
| Capex / Sales | 0.92% | 1.44% | 0.78% | 0.59% | 0.27% | 0.14% |
| Announcement Date | 28/04/19 | 14/04/20 | 29/04/21 | 29/04/22 | 21/04/23 | 29/04/24 |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -18.66% | 1.57B | |
| +13.43% | 78.69B | |
| +9.69% | 50.96B | |
| +3.49% | 48.2B | |
| +20.18% | 43.97B | |
| +13.73% | 41.9B | |
| +26.04% | 39.87B | |
| +6.85% | 30.84B | |
| -1.87% | 29.08B | |
| +13.01% | 23.04B |
- Stock Market
- Equities
- 000627 Stock
- Financials Hubei Biocause Pharmaceutical Co., Ltd.